IR_propancbiopharma
Sep 17, 4:24 PM
RAS inhibitors and PRP are designed to address different layers of tumor biology.
$RVMD and
$ERAS target oncogenic RAS signaling. PRP takes a different approach—targeting EMT, cancer stem cells and the tumor microenvironment, mechanisms associated with resistance, recurrence, and metastasis.
For
$PPCB, this creates a scientific rationale for exploring PRP alongside or following RAS-targeted therapies. As the RAS field expands, PRP’s differentiated mechanism could open multiple development paths—from combination to sequential or maintenance approaches.
Different mechanisms. Potentially complementary roles. A broader opportunity as the treatment landscape evolves.
$PPCB $RVMD $ERAS
